Form 4 for SILO Silo Pharma, Inc.
Accepted 2025-05-28 00:00:00 ET · period of report 2025-05-27 · accession 0001213900-25-048304 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-28 | 2025-05-27 | SILO | Weisblum Eric | CEO, Dir | P - Purchase | $0.43 | +10.0K | 197.9K | +5% | +$4,300 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-27 | P | A | 10,000 | $0.43 | 197,932 | D | — | — | (F1) This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions at prices ranging from $0.42 to $0.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |